Skip to content

Study · Animal study (in vivo) · 2006

13 results

Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure.

Cibrián D, Ajamieh H, Berlanga J, León OS, Alba JS, Kim MJ, Marchbank T, Boyle JJ, Freyre F, Garcia Del Barco D, Lopez-Saura P, Guillen G, Ghosh S, Goodlad RA, Playford RJ

Clinical science (London, England : 1979)1 May 2006Cited by 16 (Europe PMC)

PMID16417467 (opens in a new tab)DOI10.1042/cs20050374 (opens in a new tab)PepBankPUB-16417467
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In an animal ischaemia/reperfusion model, GHRP‑6 alone reduced hepatic damage.

    In plain wordsIn animals, GHRP‑6 alone reduced liver damage after interrupted and restored blood flow.

    Peptide
    GHRP-6
    Outcome
    DecreaseHepatic damage
    Study

    n: not reported in source

    Hepatic ischaemia/reperfusion
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    120 microg/kg · intraperitonealAs given in this study.

    Source sentences

    Summary
    Pre-treatment with GHRP-6 (120 microg/kg of body weight, intraperitoneally) alone truncated these effects by 50-85% (all P<0.05) and an additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/kg of body weight, intraperitoneally).
    1 context sentence
    Summary · context
    In vivo studies showed that, compared with baseline values, ischaemia/reperfusion caused marked hepatic and intestinal damage (histological scoring), neutrophilic infiltration (myeloperoxidase assay; 5-fold increase) and lipid peroxidation (malondialdehyde assay; 4-fold increase).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In an animal ischaemia/reperfusion model, GHRP‑6 alone reduced intestinal damage.

    In plain wordsIn animals, GHRP‑6 alone reduced intestinal damage after interrupted and restored blood flow.

    Peptide
    GHRP-6
    Outcome
    DecreaseIntestinal damage
    Study

    n: not reported in source

    Hepatic ischaemia/reperfusion
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 microg/kg · intraperitonealAs given in this study.

    Source sentences

    Summary
    Pre-treatment with GHRP-6 (120 microg/kg of body weight, intraperitoneally) alone truncated these effects by 50-85% (all P<0.05) and an additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/kg of body weight, intraperitoneally).
    1 context sentence
    Summary · context
    In vivo studies showed that, compared with baseline values, ischaemia/reperfusion caused marked hepatic and intestinal damage (histological scoring), neutrophilic infiltration (myeloperoxidase assay; 5-fold increase) and lipid peroxidation (malondialdehyde assay; 4-fold increase).
  3. 03AnimalAnimal study (in vivo)Mechanism

    In an animal ischaemia/reperfusion model, GHRP‑6 alone reduced neutrophilic infiltration.

    In plain wordsIn animals, GHRP‑6 alone reduced neutrophil infiltration after interrupted and restored blood flow.

    Peptide
    GHRP-6
    Outcome
    DecreaseNeutrophilic infiltration
    Study

    n: not reported in source

    Hepatic ischaemia/reperfusion
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    120 microg/kg · intraperitonealAs given in this study.

    Source sentences

    Summary
    Pre-treatment with GHRP-6 (120 microg/kg of body weight, intraperitoneally) alone truncated these effects by 50-85% (all P<0.05) and an additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/kg of body weight, intraperitoneally).
    1 context sentence
    Summary · context
    In vivo studies showed that, compared with baseline values, ischaemia/reperfusion caused marked hepatic and intestinal damage (histological scoring), neutrophilic infiltration (myeloperoxidase assay; 5-fold increase) and lipid peroxidation (malondialdehyde assay; 4-fold increase).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In an animal ischaemia/reperfusion model, GHRP‑6 alone reduced lipid peroxidation.

    In plain wordsIn animals, GHRP‑6 alone reduced lipid oxidation after interrupted and restored blood flow.

    Peptide
    GHRP-6
    Outcome
    DecreaseLipid peroxidation
    Study

    n: not reported in source

    Hepatic ischaemia/reperfusion
    Outcome group
    Inflammation markers · Whole body
    Studied dose
    120 microg/kg · intraperitonealAs given in this study.

    Source sentences

    Summary
    Pre-treatment with GHRP-6 (120 microg/kg of body weight, intraperitoneally) alone truncated these effects by 50-85% (all P<0.05) and an additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/kg of body weight, intraperitoneally).
    1 context sentence
    Summary · context
    In vivo studies showed that, compared with baseline values, ischaemia/reperfusion caused marked hepatic and intestinal damage (histological scoring), neutrophilic infiltration (myeloperoxidase assay; 5-fold increase) and lipid peroxidation (malondialdehyde assay; 4-fold increase).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In an animal ischaemia/reperfusion model, GHRP‑6 alone reduced lung injury.

    In plain wordsIn animals, GHRP‑6 alone reduced lung injury after interrupted and restored blood flow.

    Peptide
    GHRP-6
    Outcome
    DecreaseLung injury
    Study

    n: not reported in source

    Hepatic ischaemia/reperfusion
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    120 microg/kg · intraperitonealAs given in this study.

    Source sentences

    Summary
    Lung and renal injuries were also reduced by these pre-treatments.
    1 context sentence
    Summary · context
    Pre-treatment with GHRP-6 (120 microg/kg of body weight, intraperitoneally) alone truncated these effects by 50-85% (all P<0.05) and an additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/kg of body weight, intraperitoneally).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In an animal ischaemia/reperfusion model, GHRP‑6 alone reduced renal injury.

    In plain wordsIn animals, GHRP‑6 alone reduced kidney injury after interrupted and restored blood flow.

    Peptide
    GHRP-6
    Outcome
    DecreaseRenal injury
    Study

    n: not reported in source

    Hepatic ischaemia/reperfusion
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    120 microg/kg · intraperitonealAs given in this study.

    Source sentences

    Summary
    Lung and renal injuries were also reduced by these pre-treatments.
    1 context sentence
    Summary · context
    Pre-treatment with GHRP-6 (120 microg/kg of body weight, intraperitoneally) alone truncated these effects by 50-85% (all P<0.05) and an additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/kg of body weight, intraperitoneally).
  7. 07LabIn vitro (cells)Efficacy outcome

    In IEC-6 cells, GHRP‑6 increased migration threefold.

    In plain wordsIn cells, GHRP‑6 increased intestinal cell migration.

    Peptide
    GHRP-6
    Outcome
    IncreaseIEC-6 migration
    Study

    ratn: not reported in source

    IEC-6 intestinal epithelial cells
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Migration increase
    3 fold
    IEC-6 and HT29 cells

    Source sentences

    Summary
    In vitro studies showed that GHRP-6 directly influenced gut epithelial function as its addition caused a 3-fold increase in the rate of cell migration of IEC-6 and HT29 cells (P<0.01), but did not increase proliferation ([3H]thymidine incorporation).
    1 context sentence
    Summary · context
    In the present study, we examined the effect of synthetic GHRP-6 (growth hormone-releasing peptide-6) on cell migration and proliferation using rat intestinal epithelial (IEC-6) and human colonic cancer (HT29) cells as in vitro models of injury.
  8. 08LabIn vitro (cells)Efficacy outcome

    In HT29 cells, GHRP‑6 increased migration threefold.

    In plain wordsIn cells, GHRP‑6 increased colon cancer cell migration.

    Peptide
    GHRP-6
    Outcome
    IncreaseHT29 migration
    Study

    humann: not reported in source

    HT29 colonic cancer cells
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Migration increase
    3 fold
    IEC-6 and HT29 cells

    Source sentences

    Summary
    In vitro studies showed that GHRP-6 directly influenced gut epithelial function as its addition caused a 3-fold increase in the rate of cell migration of IEC-6 and HT29 cells (P<0.01), but did not increase proliferation ([3H]thymidine incorporation).
    1 context sentence
    Summary · context
    In the present study, we examined the effect of synthetic GHRP-6 (growth hormone-releasing peptide-6) on cell migration and proliferation using rat intestinal epithelial (IEC-6) and human colonic cancer (HT29) cells as in vitro models of injury.
  9. 09LabIn vitro (cells)Efficacy outcome

    In IEC-6 cells, GHRP‑6 did not increase proliferation.

    In plain wordsIn cells, GHRP‑6 did not increase intestinal cell proliferation.

    Peptide
    GHRP-6
    Outcome
    Direction not reportedIEC-6 proliferation
    Study

    ratn: not reported in source

    IEC-6 cells
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro studies showed that GHRP-6 directly influenced gut epithelial function as its addition caused a 3-fold increase in the rate of cell migration of IEC-6 and HT29 cells (P<0.01), but did not increase proliferation ([3H]thymidine incorporation).
    1 context sentence
    Summary · context
    In the present study, we examined the effect of synthetic GHRP-6 (growth hormone-releasing peptide-6) on cell migration and proliferation using rat intestinal epithelial (IEC-6) and human colonic cancer (HT29) cells as in vitro models of injury.
  10. 10LabIn vitro (cells)Efficacy outcome

    In HT29 cells, GHRP‑6 did not increase proliferation.

    In plain wordsIn cells, GHRP‑6 did not increase colon cancer cell proliferation.

    Peptide
    GHRP-6
    Outcome
    Direction not reportedHT29 proliferation
    Study

    humann: not reported in source

    HT29 cells
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro studies showed that GHRP-6 directly influenced gut epithelial function as its addition caused a 3-fold increase in the rate of cell migration of IEC-6 and HT29 cells (P<0.01), but did not increase proliferation ([3H]thymidine incorporation).
    1 context sentence
    Summary · context
    In the present study, we examined the effect of synthetic GHRP-6 (growth hormone-releasing peptide-6) on cell migration and proliferation using rat intestinal epithelial (IEC-6) and human colonic cancer (HT29) cells as in vitro models of injury.

Studies that did not test the peptide alone3

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 11AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In an animal ischaemia/reperfusion model, GHRP‑6 with EGF provided additional protection compared with GHRP‑6 alone.

    In plain wordsIn animals, GHRP‑6 with EGF provided more protection than GHRP‑6 alone.

    Peptide
    GHRP-6
    Outcome
    IncreaseAdditional protection with EGF
    Study

    n: not reported in source

    Hepatic ischaemia/reperfusion
    Comparator
    GHRP-6 alone
    Outcome group
    Gastrointestinal protection · Whole body

    Source sentences

    Summary
    Pre-treatment with GHRP-6 (120 microg/kg of body weight, intraperitoneally) alone truncated these effects by 50-85% (all P<0.05) and an additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/kg of body weight, intraperitoneally).

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 12AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In an animal ischaemia/reperfusion model, GHRP‑6 with EGF reduced lung injury.

    In plain wordsIn animals, GHRP‑6 with EGF reduced lung injury after interrupted and restored blood flow.

    Peptide
    GHRP-6
    Outcome
    DecreaseLung injury with GHRP-6 plus EGF
    Study

    n: not reported in source

    Hepatic ischaemia/reperfusion
    Outcome group
    Lung injury and fibrosis · Respiratory

    Source sentences

    Summary
    Lung and renal injuries were also reduced by these pre-treatments.
    1 context sentence
    Summary · context
    Pre-treatment with GHRP-6 (120 microg/kg of body weight, intraperitoneally) alone truncated these effects by 50-85% (all P<0.05) and an additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/kg of body weight, intraperitoneally).

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 13AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In an animal ischaemia/reperfusion model, GHRP‑6 with EGF reduced renal injury.

    In plain wordsIn animals, GHRP‑6 with EGF reduced kidney injury after interrupted and restored blood flow.

    Peptide
    GHRP-6
    Outcome
    DecreaseRenal injury with GHRP-6 plus EGF
    Study

    n: not reported in source

    Hepatic ischaemia/reperfusion
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Lung and renal injuries were also reduced by these pre-treatments.
    1 context sentence
    Summary · context
    Pre-treatment with GHRP-6 (120 microg/kg of body weight, intraperitoneally) alone truncated these effects by 50-85% (all P<0.05) and an additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/kg of body weight, intraperitoneally).

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.